世界各地的Adalimumab:产品特征和患者支持系统的比较分析
Tsz Hong Yiu1, Emilia Anderson2, Wai Keung Leung3
1Department of Gastroenterology, The University of Sydney, Footscray, VIC, Australia.
Therapeutic advances in gastroenterology
|October 8, 2025
概括
阿达利穆马布生物类似药在全球范围内提供多种配方和患者支持. 本综述指导处方医生根据患者需求和可用的支持系统选择最佳的阿达利穆马布产品.
科学领域:
- 药理学和药物开发领域
- 医疗保健服务研究 医疗服务研究
背景情况:
- 阿达利穆马布发明者专利的过期导致生物类似药的可用性增加.
- 在阿达利穆马布生物类似剂之间存在显著的非药理学差异.
研究的目的:
- 为了比较原始阿达利穆马布与全球可用的生物类似药物.
- 根据配方和患者支持,指导处方医生选择合适的阿达利穆马布产品.
主要方法:
- 全球药物注册表和产品信息文件的综合审查.
- 数据收集于2024年9月完成,包括对9个国家的患者支持系统的专家评估.
- 全球29种阿达利穆马布产品的比较,包括原始物和生物类似物.
主要成果:
- 突出优惠的产品特性:输送装置,度,酸盐含量,剂量范围,乳含量和保质期.
- 确定了各国患者支持服务的显著差异.
- 澳大利亚,美国和加拿大提供全面的患者支持系统.
结论:
- 阿达利穆马布产品在配方,剂量,保质期和患者支持方面表现出全球的多样性.
- 临床医生可以使用比较表来为个别患者选择最佳的阿达利穆马布选择.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
233
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
233
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
149
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
149
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
178
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
178
Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490


